Browsing Tag
Zanvastro
1 post
Zanvastro approval validates Ionis Pharmaceuticals neurology strategy, but how large is the market?
Ionis Pharmaceuticals has secured the first FDA approval for Alexander disease with Zanvastro, a quarterly RNA-targeted treatment priced at $285,000 per dose, while the ultra-rare population limits its standalone commercial ceiling.